Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Chondroitin Sulphate A Binding Domains: Potential Vaccine for Malaria

Posted Feb 27 2011 7:00pm

Description of Invention:
The subject invention is related to a potential vaccine against malaria, and in particular to a vaccine that can prevent malaria infection in pregnant women. The invention relates to the identification of chondroitin sulphate A (CSA) binding domains in var2CSA homologs from different parasite strains. Malaria in pregnancy is a serious complication associated with the parasitized erythrocyte (PE) sequestration in the placenta. With successive pregnancies, pregnant women develop antibodies that recognize placental variants worldwide suggesting these isolates express conserved determinants. Plasmodium falciparum encodes multiple copies of an erythrocyte surface adhesion ligands called var genes. Recent work suggests that two different var genes (var1CSA and var2CSA) could have an important role in PE binding to chondroitin sulphate A (CSA), a primary placental adherence receptor. It has now been shown that var2CSA is transcribed in CSA-binding parasites and that the disruption of var2CSA results in the inability of the parasites to recover the CSA-binding phenotype. Furthermore, when expressed in Chinese hamster ovary (CHO) cells, three Duffy binding-like domains (DBL2-X, DBL3-X and DBL6-epsilon) from var2CSA revealed strong and specific binding to CSA. The identification of multiple binding domains in var2CSA is envisioned as forming the basis of a vaccine against malaria, especially in pregnancy.

Inventors:
Louis H Miller (NIAID)


Patent Status:
HHS, Reference No. E-221-2004/0
PCT, Application No. PCT/US2005/035486 filed 30 Sep 2005


Licensing Status:
In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.


Portfolios:
Infectious Diseases
Infectious Diseases - Vaccines



For Licensing Information Please Contact:
Admin. Licensing Spec-InfectDis
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: anos@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220


Ref No: 1143

Updated: 02/2011

Post a comment
Write a comment:

Related Searches